10 active not recruiting, 5 completed, 4 terminated, 1 not yet recruiting. 22 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Active not recruiting 10, Completed 5, Terminated 4, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 2, Completed 2 |
Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2024-01-04 | 2026-10-15 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer Erdafitinib Intravesical Delivery System - Non-Muscle Invasive Bladder Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 235 | 2022-04-11 | 2026-11-03 |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer Erdafitinib - Bladder Cancer, Recurrent Bladder Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2022-02-17 | 2026-09-02 |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Erdafitinib - Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2021-07-15 | 2026-02-06 |
| Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Abiraterone Acetate, Enzalutamide, Erdafitinib - Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma | Phase 2 | Terminated | University of Washington | 3 | 2020-04-27 | 2023-09-28 |
| A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C) - Urinary Bladder Neoplasms | Phase 2 | Completed | Janssen Research & Development, LLC | 107 | 2020-02-28 | 2026-02-24 |
| A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations Erdafitinib - Advanced Solid Tumor | Phase 2 | Completed | Janssen Research & Development, LLC | 316 | 2019-11-20 | 2026-09-17 |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| FGFR Inhibitor in FGFR Dysregulated Cancer ERDAFITINIB - Lung Cancer, NSCLC | Phase 2 | Terminated | Lung Cancer Group Cologne | 22 | 2019-03-25 | 2023-06-09 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-08-20 | 2026-09-15 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-07-03 | 2026-10-15 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-11-13 |
| A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer Erdafitinib, Cetrelimab, Cisplatin - Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 125 | 2018-04-05 | 2026-08-28 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement JNJ-42756493, Dexamethasone - Multiple Myeloma, Relapsed/Refractory | Phase 2 | Terminated | University Health Network, Toronto | 20 | 2017-06-13 | 2020-09-17 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma Erdafitinib - Neoplasm | Phase 2 | Completed | Janssen Research & Development, LLC | 35 | 2016-07-08 | 2025-04-27 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
Showing 20 of 22. Sign in to see all of them.
Glioma (4) · Multiple Myeloma (4) · Urinary Bladder Neoplasms (4) · Non-Muscle Invasive Bladder Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Esophageal Neoplasms (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Lung Neoplasms (2) · Lymphoma (2)
Janssen Research & Development, LLC (7) · National Cancer Institute (NCI) (7) · Lung Cancer Group Cologne (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Multiple Myeloma Research Consortium (1) · Peking University Shenzhen Hospital (1) · The Netherlands Cancer Institute (1) · University Health Network, Toronto (1) · University of Washington (1)
United States (15) · South Korea (7) · Taiwan (6) · Germany (5) · Spain (5) · Belgium (4) · China (4) · France (4) · United Kingdom (4) · Australia (3) · Brazil (3) · Canada (3) · Italy (3) · Japan (3) · Poland (3)
Alain C Mita (2) · Alice Lee (1) · Di Maria Jiang (1) · Donald W Parsons (1) · E.E. Voest, prof. (1) · Eugene Pietzak, MD (1) · Hearn J Cho, M.D., Ph.D. (1) · Keith T Flaherty (1) · Lucia Nogova, MD (1) · Michael Schweizer (1) · Paul Corn (1) · Suzanne Trudel, M.D. (1)
PMID 26586415, PMID 31340094, PMID 31401903, PMID 32463741, PMID 33048619, PMID 33591402, PMID 34125951, PMID 34977972, PMID 35030333, PMID 35086719, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35598186, PMID 36351402, PMID 36639200, PMID 36870947, PMID 37053535, PMID 37322121, PMID 37424386, PMID 37541273, PMID 37934000, PMID 38591867, PMID 38630551, PMID 39138436, PMID 39666929, PMID 39693587, PMID 39913886, PMID 39971605, PMID 40675687, PMID 40865033, PMID 41066729, PMID 41166674, PMID 41538748, PMID 41986720, PMID 42456086, PMID 42686334
2023 (5), U10CA180820 (3), 2019 (2), U10CA180886 (2), UM1CA186644 (2), 2014 (1), 2017 (1), 2018 (1), U24CA196172 (1), UM1CA081457 (1)